Brittany McMurren
Optometrist · San Diego, CANPI 1104243815
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Lumenis BE Inc at 29.3% of the total. Reporting peaked in 2022 at $8,371 and has fallen 58.6% since, to $3,463 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $220.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$9K
- Biotissue Holdings Inc.$5K
- Oculus, Inc.$4K
- Optovue, Inc.$3K
- Nordic Pharma, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- plus $6K from 18 others
Across 5 payments — averaging $13,004 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$65K
What the payments were for
- Consulting fees$7,37525%
- Speaking & faculty fees$10,47235%
- Travel & lodging$3951%
- Food & beverage$11,01137%
- Entertainment$3331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 4 | $8,665 |
| Biotissue Holdings Inc. | 24 | $5,374 |
| Oculus, Inc. | 4 | $3,690 |
| Optovue, Inc. | 3 | $3,000 |
| Nordic Pharma, Inc. | 1 | $2,100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $1,036 |
| Bausch & Lomb Americas Inc. | 11 | $892 |
| Alcon | 11 | $670 |
| Sight Sciences, Inc. | 7 | $547 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $511 |
| Coopervision Inc. | 9 | $510 |
| AbbVie(2 entities) | 11 | $476 |
| Optos, Inc. | 4 | $432 |
| LKC Technologies, Inc. | 2 | $232 |
| Topcon Healthcare, Inc. | 2 | $229 |
| Shire North American Group Inc | 4 | $223 |
| Dompe US, Inc. | 3 | $186 |
| Maculogix, Inc. | 2 | $168 |
| Harrow Eye, LLC | 2 | $160 |
| Johnson & Johnson Vision Care, Inc. | 1 | $153 |
| Oyster Point Pharma, Inc. | 1 | $115 |
| Glaukos Corporation | 1 | $91 |
| Tarsus Pharmaceuticals, Inc. | 1 | $89 |
| Kala Pharmaceuticals, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$8,665
- OCULUS Keratograph 5M$3,690
- Prokera$2,547
- AngioVue$2,500
- Lacrifill$2,100
- PANORAMIC OPHTHALMOSCOPE$666
- OCT OPHTHALMOSCOPE$666
- iVue$500
- INFUSE$483
- XIIDRA$392
- NFC-700$333
- TEARCARE SYSTEM$272
- MIEBO$271
- LOTEMAX SM$240
- AmnioGraft$237
- AdaptDx$154
- Acuvue$153
- DAILIES$144
- VEVYE$137
- TRYPTYR$128
How this compares
$29,587 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 13 | $9,833 |
| Prednisolone Acetate | 11 | $414 |
| Latanoprost | 11 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo | $892 | $9,83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in San Diego
- Jason TuSan Diego$351K
- Alicia LauSan Diego$300K
- Melody TavakoliSan Diego$267K
- Brian ChouSan Diego$243K
- David GeffenSan Diego$144K
- Elliott ShapiroSan Diego$135K
- Keith WanSan Diego$87K
- Jennifer ChinnSan Diego$67K
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.